Related references
Note: Only part of the references are listed.Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Haifa Kathrin Al-Ali et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Management of myelofibrosis after ruxolitinib failure
Claire N. Harrison et al.
ANNALS OF HEMATOLOGY (2020)
UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN
Claire Harrison et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Hans Michael Kvasnicka et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
Claire N. Harrison et al.
ANNALS OF HEMATOLOGY (2017)
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
BLOOD (2016)
Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey
Ruben Mesa et al.
BMC CANCER (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Share Paper
